FibroGen, Inc (FGEN) financial statements (2020 and earlier)

Company profile

Business Address 409 ILLINOIS STREET
SAN FRANCISCO, CA 94158
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments534621736253181
Cash and cash equivalents12689674174153
Short-term investments407532627928
Receivables15464121015
Inventory, net of allowances, customer advances and progress billings7    
Inventory7    
Prepaid expense6    
Other current assets2    
Other undisclosed current assets 5134
Total current assets:702690749267201
Noncurrent Assets
Finance lease, right-of-use asset40
Operating lease, right-of-use asset2
Property, plant and equipment43127129124129
Long-term investments and receivables61561171132
Long-term investments61561171132
Restricted cash and investments    7
Other noncurrent assets93522
Other undisclosed noncurrent assets0456 
Total noncurrent assets:155191150203270
TOTAL ASSETS:857881899470471
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities675695754
Accounts payable69667
Accrued liabilities 66645148
Deferred revenue0
Debt12    
Deferred revenue and credits8813
Contract with customer, liability14
Other undisclosed current liabilities84    
Total current liabilities:10389776567
Noncurrent Liabilities
Long-term debt and lease obligation38    
Finance lease, liability38
Liabilities, other than long-term debt16414912411794
Deferred revenue and credits11611190
Deferred revenue99
Contract with customer, liability136
Deferred rent credit 3
Other liabilities6410865
Other undisclosed noncurrent liabilities18114115112112
Total noncurrent liabilities:219263239229207
Total liabilities:322352316294274
Stockholders' equity
Stockholders' equity attributable to parent516509563156178
Common stock11111
Additional paid in capital1,3011,2261,160626587
Accumulated other comprehensive loss(1)(2)(2)(1)(2)
Accumulated deficit(785)(716)(596)(470)(408)
Stockholders' equity attributable to noncontrolling interest1919191919
Total stockholders' equity:535528582175197
TOTAL LIABILITIES AND EQUITY:857881899470471

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:257213126180181
Operating expenses(346)(300)(248)(233)(258)
Operating loss:(89)(87)(123)(54)(78)
Interest and debt expense(3)(11)(10)(11)(11)
Loss from continuing operations before equity method investments, income taxes:(92)(98)(132)(64)(89)
Other undisclosed income from continuing operations before income taxes1612633
Loss from continuing operations before income taxes:(77)(86)(126)(62)(86)
Income tax expense (benefit)(0)(0)(0)0(0)
Net loss available to common stockholders, diluted:(77)(86)(126)(62)(86)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(77)(86)(126)(62)(86)
Other comprehensive income (loss)11(1)11
Comprehensive loss, net of tax, attributable to parent:(76)(86)(127)(61)(84)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: